Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment

被引：0
|
作者：
Graf, Christiana [1 ]
Degasperi, Elisabetta [2 ]
D'Ambrosio, Roberta [2 ]
Llaneras, Jordi [3 ]
Vermehren, Johannes [1 ]
Dultz, Georg [1 ]
Wetzstein, Nils [4 ]
Herrmann, Eva [5 ]
Zeuzem, Stefan [1 ]
Buti, Maria
Lampertico, Pietro
Dietz, Julia [1 ]
Sarrazin, Christoph [1 ,6 ]
机构：
[1] Univ Hosp Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[3] UAB Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Dept Med, Barcelona, Spain
[4] Univ Hosp Frankfurt, Dept Internal Med Infect Dis, Frankfurt, Germany
[5] Goethe Univ Frankfurt, Inst Biostatist & Math Modeling, Frankfurt, Germany
[6] St Josefs Hosp, Med Klin II, Wiesbaden, Germany
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OS-129-YI
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [31] Sofosbuvir plus velpatasvir plus voxilaprevir for the treatment of hepatitis C infection
    Cory, Theodore J.
    Mu, Ying
    Gong, Yuqing
    Kodidela, Sunitha
    Kumar, Santosh
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (07) : 749 - 757
  • [32] Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
    Young-A Heo
    Emma D. Deeks
    Drugs, 2018, 78 : 577 - 587
  • [33] EFFICACY OF SOFOSBUVIR/ VELPATASVIR/ VOXILAPREVIR IN NAIVE CHRONIC HEPATITIS C PATIENTS: REAL LIFE STUDY
    Guner, Hatice Rahmet
    Yamazhan, Tansu
    Karabay, Oguz
    Inci, Ayse
    Yilmaz, Gurdal
    Aydin, Ozlem Altuntas
    Caglar, Yesim
    Senel, Ilknur
    Yildirim, Arzu Altuncekic
    Zerdali, Esra Yerlikaya
    Tatar, Bengu Gireniz
    Tabak, Fehmi
    HEPATOLOGY, 2023, 78 : S719 - S719
  • [34] Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
    Heo, Young-A
    Deeks, Emma D.
    DRUGS, 2018, 78 (05) : 577 - 587
  • [35] Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
    Llaneras, Jordi
    Riveiro-Barciela, Mar
    Lens, Sabela
    Diago, Moises
    Cachero, Alba
    Garcia-Samaniego, Javier
    Conde, Isabel
    Arencibia, Ana
    Arenas, Juan
    Gea, Francisco
    Torras, Xavier
    Luis Calleja, Jose
    Antonio Carrion, Jose
    Fernandez, Inmaculada
    Maria Morillas, Rosa
    Miguel Rosales, Jose
    Carmona, Isabel
    Fernandez-Rodriguez, Conrado
    Hernandez-Guerra, Manuel
    Llerena, Susana
    Bernal, Vanesa
    Turnes, Juan
    Gonzalez-Santiago, Jesus M.
    Montoliu, Silvia
    Figueruela, Blanca
    Badia, Ester
    Delgado, Manuel
    Fernandez-Bermejo, Miguel
    Inarrairaegui, Mercedes
    Manuel Pascasio, Juan
    Esteban, Rafael
    Marino, Zoe
    Buti, Maria
    JOURNAL OF HEPATOLOGY, 2019, 71 (04) : 666 - 672
  • [36] Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals
    Ruiz-Boy, Sonia
    Rodriguez-Reyes, Montserrat
    Sotoca-Momblona, Jose Miguel
    MEDICINA CLINICA, 2021, 157 (02): : 85 - 86
  • [37] Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
    Yu-Ting Huang
    Yung-Yu Hsieh
    Wei-Ming Chen
    Shui-Yi Tung
    Kuo-Liang Wei
    Chen-Heng Shen
    Kao-Chi Chang
    Chung-Kuang Lu
    Chih-Wei Yen
    Sheng-Nan Lu
    Chao-Hung Hung
    Te-Sheng Chang
    BMC Gastroenterology, 21
  • [38] Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
    Huang, Yu-Ting
    Hsieh, Yung-Yu
    Chen, Wei-Ming
    Tung, Shui-Yi
    Wei, Kuo-Liang
    Shen, Chen-Heng
    Chang, Kao-Chi
    Lu, Chung-Kuang
    Yen, Chih-Wei
    Lu, Sheng-Nan
    Hung, Chao-Hung
    Chang, Te-Sheng
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [39] Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/ pibrentasvir for genotype 6 chronic hepatitis C
    Chen, Jyh-Jou
    Chiu, Yen-Cheng
    Lee, Pei-Lun
    Tung, Hung-Da
    Chiu, Hung-Chih
    Chien, Shih-Chieh
    Cheng, Pin-Nan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (11) : 2265 - 2272
  • [40] HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C
    O'Loan, Joss
    Balcomb, Anne
    Baker, David
    Doyle, Joseph
    Godfrey, Daniel
    Kozminsky, Michael
    Mertens, Michael
    Vanstraelen, Kim
    Young, Matt
    JOURNAL OF HEPATOLOGY, 2020, 73 : S346 - S346
12345